Duke Cancer Center Raleigh — Raleigh, North Carolina

Duke Cancer Center Raleigh is a clinical research site located in Raleigh, North Carolina, United States 27609.

Crixeo Clinical Trials Trust Score: 27/100 (FAILING). This profile has not yet been claimed by the site owner.

Duke Cancer Center Raleigh has participated in 49 clinical trials with 44 currently active.

Therapeutic areas: Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8.

Sponsors: SWOG Cancer Research Network, NRG Oncology, ECOG-ACRIN Cancer Research Group.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Raleigh

Browse all research sites in North Carolina · View every site in Raleigh

Sponsor Feasibility Report

Trust Score: 27/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Duke Cancer Center Raleigh?

Duke Cancer Center Raleigh has a Crixeo Trust Score of 27/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Duke Cancer Center Raleigh conducted?

Duke Cancer Center Raleigh has 49 clinical trials on record, with 44 currently active. Their work covers Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8.

Is Duke Cancer Center Raleigh accredited by Crixeo Clinical Trials?

Duke Cancer Center Raleigh has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Duke Cancer Center Raleigh?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.